RAS(ON) inhibitor daraxonrasib shows promising results in advanced pancreatic cancer
The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated RAS-mutant metastatic pancreatic cancer, according to a Phase I/II first-in-human trial led by ...
May 7, 2026
0
5









